Loading...
Loading...
A report from Goldman Sachs reiterates its Buy rating on Humana
HUM.
The report states, “As expected, 3Q upside was driven primarily by a continuation of favorable medical cost trends. The consolidated medical cost ratio (
MCR) was 80.7% vs. our 82.5%, partly offset by a consolidated OCR (operating cost ratio) of 14.8% vs. our 14.6%. Enrollment was in line or ahead of our model as were both premium (+1% vs. our model) and (+3% vs. our model) fee revenues."
HUM closed Friday at $80.35.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in